TargEDys

TargEDys

Solutions to regulate appetite. Learn more

Financials

Estimates*

Edit
Revenues, earnings & profits over time
EUR2015201620172018201920202021
Revenues<1m--<1m<1m1.2m<1m
% growth----561 %562 %(42 %)
EBITDA(<1m)(1.1m)(2.1m)(2.8m)(2.9m)(1.6m)(1.6m)
% EBITDA margin(71904 %)--(10391 %)(1645 %)(140 %)(242 %)
Profit(<1m)(1.0m)(1.8m)(2.3m)(2.5m)(1.4m)(1.4m)
% profit margin(62840 %)--(8557 %)(1413 %)(121 %)(208 %)

Source: Dealroom estimates

  • Edit
DateInvestorsAmountRound
-

N/A

-
*

N/A

Support Program

€5.8m

Series A
*

€1.1m

Valuation: €29.0m

-25.3x EV/LTM EBITDA

Early VC
*

€3.5m

Series A
*

N/A

Acquisition
Total Funding$11.4m

Recent News about TargEDys

Edit
More about TargEDysinfo icon
Edit

TargEDys is a pioneering company specializing in microbiome-based solutions aimed at weight management and optimal nutrition. Operating within the healthcare and biotechnology sectors, TargEDys collaborates with renowned researchers to develop precision probiotics that target specific health outcomes. The company's unique approach is backed by 10 families of patents, ensuring robust intellectual property protection. TargEDys primarily serves healthcare providers, nutritionists, and consumers seeking scientifically-backed nutritional supplements. The business model revolves around research and development, patent licensing, and direct sales of their probiotic products. Revenue is generated through product sales, partnerships, and licensing agreements. TargEDys' commitment to innovation and scientific rigor positions it as a leader in the next generation of probiotics.

Keywords: microbiome, probiotics, weight management, nutrition, healthcare, biotechnology, precision probiotics, patent, research, innovation.

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.